Figure 1





Figure 2





A
hGM-CSF / (ng/ml)
10
5
0
0
0.1
1
10
10²
10³
10⁴
antigen / (ng/ml)
CPS type 4
αGalCer
αGalCer-CPS tpye 4 (887a old)
αGalCer-CPS tpye 4 (887a new)
αGalCer-CPS tpye 4 (887b)
B
hGM-CSF / (ng/ml)
2
1
0
0
10³
10⁴
antigen / (ng/ml)
CPS type 4
αGalCer
αGalCer-CPS tpye 4 (887a old)
αGalCer-CPS tpye 4 (887a new)
αGalCer-CPS tpye 4 (887b)

Figure 3



A
total immunoglobulin
OD
2.0
1.5
1.0
0.5
0.0
10
100
sera dilution
CPS 1
CPS 2
CPS 3
αGalCer-CPS 1
αGalCer-CPS 2
αGalCer-CPS 3
naïve
B
total immunoglobulin
OD
1.5
1.0
0.5
0.0
100
bg
sera dilution
WT 1
WT 2
WT 3
CD1d-/- 1
CD1d-/- 2
CD1d-/- 3

Figure 4



A
IgG1
OD
0.3
0.2
0.1
0.0
WT 1
WT 2
CD1d-/- 1
CD1d-/- 2
100
bg
sera dilution
B
total immunoglobulin
OD
1.0
0.5
0.0
WT 1
WT 3
WT 1
WT 3
100
bg
sera dilution

Figure 5

Figure 6

Hybridoma	Heavy chain	CDR1	CDR2	CDR3	Mutations (aa/nuc)*
6C2	γ1	GYSITSGYS	I-HY--SGYT	ARSANYGPM-----DYWGQG	4/6
2F4	γ1	GFSLTS-YG	I--W-SDGST	ARHSKLGQF-----AYWGQG	0/1
1B4	γ1	GYSITSGYS	I-HY--SGYT	ARSANYGPM-----DYWGQG	4/6
12F10	γ1	GYSITSGYS	I-HY--SGST	ARSANYGPM-----DYWGQG	2/5
2B5	γ2a	GFSLTS-YG	I--W-SGGST	VRNGVYRDF-----AYWGQG	0/0
26D2	γ3	GFSLTS-YG	I--W-GDGST	AKIYYYGRN--YAMDYWGQG	1/2
26H11	μ	GYTFTS-YY	I-IYPGNVNT	ARGGNYYYY---AMDYWGQG	0/0
10B4	μ	GYSFTG-YN	IDPY--YGGT	ARSTGTAWF-----AYWGQG	0/0
5H3	μ	GFTFSS-YG	I-S-SGGSYT	ARLYD-GYY-VAWFAYWGQG	0/0
14D3	μ	GFSLTS-YG	I--W-SGGST	ARNSGTGWY----FDVWGAG	0/0
18 E4	μ	GFSLTS-YG	I--W-SGGST	ARNGNRAWF-----AYWGQG	0/0
16D9	μ	GYTFT-DYA	ISTY--YGNT	AR----GDW----EDYWGQG	4/9
3 E10	μ	GFSLTS-YG	I--W-SGGST	ARDGYPAWF-----AYWGQG	0/0
26F3	μ	GYTFTS-YW	I--NPSTGYT	ARGRN--HY----FDYWGQG	0/1
25B7	μ	GFSLTD-YG	I--W-GGGST	AKQGNWADY--YAMDYWGQG	0/0
25A8	μ	GYTFSR-YW	I--LPGSGTT	ARLLR---Y----FDYWGQG	3/5
21B6	μ	GYSFTG-YN	IDPY--YGGT	ARS-NWTYY--YAMDYWGQG	0/0
18G6	μ	GYSFTG-YN	IDPY--YGGT	AR-----GY---AMDYWGQG	0/0
18G6	μ	GYSITSDYA	I-SY--SGST	ARSL-YGNYGDYAMDYWGQG	0/0

SUBSTITUTE SHEET (RULE 26)

Cells	%positive
APCalone	0
APC+C	47
APC+C +12F10	60
APC+C +C15	37
APC+12F10	0
APC+C15	3





Figure 7


B
percent survival
100
50
0
0
100
200
300
hours after challenge
αGalCer-CPS
CPS



A
weight / g
24
22
20
18
16
14
0
100
200
300
hours after challenge
CPS 1
CPS 2
CPS 3
αGalCer-CPS 1
αGalCer-CPS 2
αGalCer-CPS 3

Figure 8



α Gal|Cer-CPS 1
α Gal|Cer-CPS 2
α Gal|Cer-CPS 3
α Gal|Cer-CPS 4
α Gal|Cer-CPS 5
α Gal|Cer-CPS 6
CPS 1
CPS 2
CPS 3
CPS 4
CPS 5
CPS 6
OD
0.3
0.2
0.1
0.0
100
1000
dilution
OD
0.3
0.2
0.1
0.0
100
1000
dilution

Figure 9



αGalCer-CPS 1
αGalCer-CPS 2
αGalCer-CPS 3
αGalCer-CPS 4
αGalCer-CPS 5
αGalCer-CPS 6
CPS 1
CPS 2
CPS 3
CPS 4
CPS 5
CPS 6
OD
1.0
0.8
0.6
0.4
0.2
0.0
100
1000
dilution

Figure 10